<qa>  What is the PI3Kv-akt Murine ThymomaII. For patients beginning in dose level 7 as well as the expansion cohorts, we will describe any changes in tumor expression of ER both full length and truncated forms, progesterone receptor PR, steroid receptor co-activator SRC1, SRC3, as well as the insulin-like growth factor receptor IGF1Rphosphatidylinositol 3 kinase PI3Kv-akt Murine Thymoma Viral Oncogene Homolog 1 AKTmammalian target of rapamycin mTOR pathway and proliferation-related Ki-67 antigen Ki67 after 1 cycle of treatment approximately 28 days. 